Showing results (1-10 of 230) with videos related to
Sort By:
Pageof 23
Methods in Enzymology|January 1, 1986
Optimal strategies for developing human-human monoclonal antibodiesP G Abrams, J L Rossio, H C Stevenson, et al.Blood|April 1, 1986
Relationship of the clinical response and binding of recombinant interferon alpha in patients with lymphoproliferative diseasesC R Faltynek, G L Princler, J L Rossio, et al.Journal of Biological Response Modifiers|December 1, 1985
A phase I evaluation of poly(I,C)-LC in cancer patientsH C Stevenson, P G Abrams, C S Schoenberger, et al.Hybridoma|January 1, 1985
The generation of stable human T-cell hybridomas which constitutively produce interleukin-2 and chemotactic factorK A Foon, J L Rossio, R W Schroff, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1985
A phase I trial of recombinant gamma interferon in patients with cancerK A Foon, S A Sherwin, P G Abrams, et al.The American Journal of Medicine|March 1, 1986
Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic resultsK A Foon, A E Maluish, P G Abrams, et al.Cancer Research|November 15, 1987
Fate of gamma-interferon-activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinomatosisH C Stevenson, A M Keenan, C Woodhouse, et al.The New England Journal of Medicine|November 1, 1984
Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferonK A Foon, S A Sherwin, P G Abrams, et al.Cancer|December 1, 1984
Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancerR K Oldham, G B Thurman, J E Talmadge, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 1, 1983
Determination of the optimal human cell lines for development of human hybridomasP G Abrams, J A Knost, G Clarke, et al.Pageof 23